Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s ...

Amid a transformation effort under CEO Christophe Bourdon, Danish dermatology expert Leo Pharma is embarking on another round ...

Mankind Pharma, controlled by billionaire brothers Ramesh and Rajeev Juneja, announced in July plans to buy Mumbai-based ...

Generic drug giant Teva Pharmaceuticals has agreed to pay $450 million to settle two cases brought by the Department of ...

The Delhi High Court recently observed that courts need to be more stringent and cautious while dealing with cases involving ...

CNBC's Karen Gilchrist weighs in on Zealand Pharma's "next generation" obesity drug candidate and its search for a global ...

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ...

AstraZeneca has bagged a cardiovascular disease candidate from China's CSPC Pharma in a deal potentially worth $2 billion.

BALLERUP, Denmark-- ( BUSINESS WIRE )--LEO Pharma today announced its commitment to achieving a net-zero climate target by ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Royalty Pharma (RPRX – Research Report), with a ...